

Josef S Smolen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4455901/publications.pdf>

Version: 2024-02-01

447
papers

73,740
citations

1799

103
h-index

593

261
g-index

454
all docs

454
docs citations

454
times ranked

36466
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2010, 62, 2569-2581. | 6.7 | 6,781 |
| 2 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977. | 0.9 | 3,366 |
| 3 | 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1580-1588. | 0.9 | 2,994 |
| 4 | Rheumatoid arthritis. <i>Lancet</i> , The, 2016, 388, 2023-2038. | 13.7 | 2,989 |
| 5 | Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2000, 343, 1594-1602. | 27.0 | 2,910 |
| 6 | Infliximab (chimeric anti-tumour necrosis factor $\hat{\pm}$ monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. <i>Lancet</i> , The, 1999, 354, 1932-1939. | 13.7 | 2,266 |
| 7 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699. | 0.9 | 1,860 |
| 8 | Treating rheumatoid arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 631-637. | 0.9 | 1,711 |
| 9 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 492-509. | 0.9 | 1,688 |
| 10 | Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor γ monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1998, 41, 1552-1563. | 6.7 | 1,560 |
| 11 | Rheumatoid arthritis. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18001. | 30.5 | 1,441 |
| 12 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 964-975. | 0.9 | 1,429 |
| 13 | Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. <i>Lancet</i> , The, 2008, 371, 987-997. | 13.7 | 1,269 |
| 14 | 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 736-745. | 0.9 | 1,265 |
| 15 | Diagnosis and Management of Rheumatoid Arthritis. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1360. | 7.4 | 1,257 |
| 16 | Dickkopf-1 is a master regulator of joint remodeling. <i>Nature Medicine</i> , 2007, 13, 156-163. | 30.7 | 1,161 |
| 17 | Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 3-15. | 0.9 | 1,114 |
| 18 | 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1400-1412. | 5.6 | 1,098 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. <i>Arthritis and Rheumatism</i> , 2004, 50, 3432-3443. | 6.7 | 1,080 |
| 20 | American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Arthritis and Rheumatism</i> , 2011, 63, 573-586. | 6.7 | 864 |
| 21 | New therapies for treatment of rheumatoid arthritis. <i>Lancet, The</i> , 2007, 370, 1861-1874. | 13.7 | 859 |
| 22 | Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. <i>Arthritis Research</i> , 2005, 7, R796. | 2.0 | 838 |
| 23 | 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159. | 0.9 | 759 |
| 24 | Therapeutic strategies for rheumatoid arthritis. <i>Nature Reviews Drug Discovery</i> , 2003, 2, 473-488. | 46.4 | 727 |
| 25 | Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. <i>Lancet, The</i> , 1999, 353, 259-266. | 13.7 | 706 |
| 26 | American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 404-413. | 0.9 | 657 |
| 27 | EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 700.1-712. | 0.9 | 609 |
| 28 | Inflammatory bone loss: pathogenesis and therapeutic intervention. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 234-250. | 46.4 | 601 |
| 29 | Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). <i>Arthritis and Rheumatism</i> , 2005, 52, 1227-1236. | 6.7 | 583 |
| 30 | Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 958-967. | 0.9 | 558 |
| 31 | Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2000, 43, 2501-2512. | 6.7 | 524 |
| 32 | EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 804-814. | 0.9 | 504 |
| 33 | Baricitinib in Patients with Refractory Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2016, 374, 1243-1252. | 27.0 | 499 |
| 34 | Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor $\hat{\pm}$ inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. <i>Lancet, The</i> , 2009, 374, 210-221. | 13.7 | 497 |
| 35 | Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17. | 0.9 | 484 |
| 36 | 2019 Update of the Joint European League Against Rheumatism and European Renal Associationâ€™European Dialysis and Transplant Association (EULAR/ERAâ€™EDTA) recommendations for the management of lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 713-723. | 0.9 | 463 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Osteoclasts are essential for TNF- α -mediated joint destruction. <i>Journal of Clinical Investigation</i> , 2002, 110, 1419-1427. | 8.2 | 437 |
| 38 | Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity states. <i>Arthritis and Rheumatism</i> , 2005, 52, 2625-2636. | 6.7 | 428 |
| 39 | Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 6-16. | 0.9 | 397 |
| 40 | Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 909-920. | 0.9 | 394 |
| 41 | 2016 update of the EULAR recommendations for the management of early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 948-959. | 0.9 | 393 |
| 42 | Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial. <i>Arthritis and Rheumatism</i> , 2006, 54, 702-710. | 6.7 | 390 |
| 43 | Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. <i>Nature Reviews Rheumatology</i> , 2015, 11, 276-289. | 8.0 | 372 |
| 44 | Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. <i>Lancet, The</i> , 2017, 390, 457-468. | 13.7 | 360 |
| 45 | Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 811-818. | 0.9 | 325 |
| 46 | Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. <i>Lancet, The</i> , 2013, 381, 918-929. | 13.7 | 311 |
| 47 | Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1101-1136. | 0.9 | 277 |
| 48 | Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 16-22. | 0.9 | 275 |
| 49 | Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1441-1447. | 0.9 | 274 |
| 50 | 2018 update of the EULAR recommendations for the management of hand osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 16-24. | 0.9 | 273 |
| 51 | A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 554-561. | 0.9 | 268 |
| 52 | Osteoclasts are essential for TNF- α -mediated joint destruction. <i>Journal of Clinical Investigation</i> , 2002, 110, 1419-1427. | 8.2 | 255 |
| 53 | Nuclear antigen histone H1 is primarily involved in lupus erythematosus cell formation. <i>Arthritis and Rheumatism</i> , 1998, 41, 1446-1455. | 6.7 | 244 |
| 54 | Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. <i>Arthritis and Rheumatism</i> , 2006, 54, 2784-2792. | 6.7 | 241 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | Essential role of microRNAâ€155 in the pathogenesis of autoimmune arthritis in mice. <i>Arthritis and Rheumatism</i> , 2011, 63, 1281-1288. | 6.7 | 240 |
| 56 | Inhibition of interleukinâ€6 receptor directly blocks osteoclast formation in vitro and in vivo. <i>Arthritis and Rheumatism</i> , 2009, 60, 2747-2756. | 6.7 | 237 |
| 57 | Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. <i>Lancet</i> , The, 2019, 393, 2303-2311. | 13.7 | 237 |
| 58 | Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. <i>Lancet</i> , The, 2014, 383, 321-332. | 13.7 | 232 |
| 59 | Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. <i>Arthritis and Rheumatism</i> , 1995, 38, 38-43. | 6.7 | 226 |
| 60 | Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. <i>Arthritis and Rheumatism</i> , 2007, 56, 3226-3235. | 6.7 | 225 |
| 61 | Proposal for a new nomenclature of disease-modifying antirheumatic drugs: Tableâ€1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 3-5. | 0.9 | 212 |
| 62 | SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1345-1350. | 0.9 | 211 |
| 63 | Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. <i>Journal of Rheumatology</i> , 2019, 46, 7-18. | 2.0 | 207 |
| 64 | A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 123-131. | 0.9 | 206 |
| 65 | Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 760-770. | 0.9 | 205 |
| 66 | EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 851-858. | 0.9 | 204 |
| 67 | Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 638-643. | 0.9 | 203 |
| 68 | A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. <i>Rheumatology</i> , 2009, 48, 1114-1121. | 1.9 | 198 |
| 69 | Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1113-1136. | 0.9 | 195 |
| 70 | Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 64-71. | 0.9 | 183 |
| 71 | Treating juvenile idiopathic arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2018-213030. | 0.9 | 183 |
| 72 | Rapid and sustained improvement in bone and cartilage turnover markers with the antiâ€interleukinâ€6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. <i>Arthritis and Rheumatism</i> , 2010, 62, 33-43. | 6.7 | 181 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1004-1009. | 0.9 | 179 |
| 74 | Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 165-174. | 0.9 | 173 |
| 75 | Efficacy and Safety of ABT494, a Selective JAK1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. <i>Arthritis and Rheumatology</i> , 2016, 68, 2857-2866. | 5.6 | 172 |
| 76 | Mixed connective tissue disease: To be or not to be?. <i>Arthritis and Rheumatism</i> , 1998, 41, 768-777. | 6.7 | 167 |
| 77 | Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 744-759. | 0.9 | 167 |
| 78 | A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities: I. Precision, sensitivity, and specificity. <i>Arthritis and Rheumatism</i> , 1999, 42, 455-464. | 6.7 | 163 |
| 79 | Heterogeneity of immunoregulatory T-cell subsets in systemic lupus erythematosus. <i>American Journal of Medicine</i> , 1982, 72, 783-790. | 1.5 | 160 |
| 80 | The changing landscape of biosimilars in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 974-982. | 0.9 | 160 |
| 81 | Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 733-739. | 0.9 | 159 |
| 82 | Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 71-87. | 0.9 | 158 |
| 83 | A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 58-64. | 0.9 | 146 |
| 84 | Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. <i>Lancet</i> , The, 2016, 388, 2763-2774. | 13.7 | 144 |
| 85 | Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: The role of acute-phase reactants. <i>Arthritis and Rheumatism</i> , 2011, 63, 43-52. | 6.7 | 141 |
| 86 | The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 495-502. | 0.9 | 136 |
| 87 | Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept) Tj ETQq1 1 0.784314 rgBT /Over therapy. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1616-1625. | 0.9 | 135 |
| 88 | The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007, 21, 663-675. | 3.3 | 134 |
| 89 | How to report radiographic data in randomized clinical trials in rheumatoid arthritis: Guidelines from a roundtable discussion. <i>Arthritis and Rheumatism</i> , 2002, 47, 215-218. | 6.7 | 132 |
| 90 | Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1102-1107. | 0.9 | 131 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Repair of Local Bone Erosions and Reversal of Systemic Bone Loss Upon Therapy with Anti-Tumor Necrosis Factor in Combination with Osteoprotegerin or Parathyroid Hormone in Tumor Necrosis Factor-Mediated Arthritis. <i>American Journal of Pathology</i> , 2004, 164, 543-555. | 3.8 | 130 |
| 92 | Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic Data. <i>Arthritis Care and Research</i> , 2018, 70, 428-438. | 3.4 | 129 |
| 93 | The Definition and Measurement of Disease Modification in Inflammatory Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2006, 32, 9-44. | 1.9 | 124 |
| 94 | A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 831-839. | 0.9 | 124 |
| 95 | Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. <i>Arthritis and Rheumatism</i> , 2011, 63, 3702-3711. | 6.7 | 122 |
| 96 | Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 687-693. | 0.9 | 119 |
| 97 | Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 114-123. | 0.9 | 118 |
| 98 | Impact of comorbidity on physical function in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 536-541. | 0.9 | 117 |
| 99 | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, ii2-ii34. | 0.9 | 114 |
| 100 | Demonstration of a new antinuclear antibody (ANTI-RA33) that is highly specific for rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1989, 32, 1515-1520. | 6.7 | 113 |
| 101 | Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1757-1764. | 0.9 | 113 |
| 102 | Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 534-542. | 0.9 | 111 |
| 103 | Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2011, 50, 381-388. | 1.9 | 109 |
| 104 | Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure. <i>Journal of Rheumatology</i> , 2013, 40, 768-780. | 2.0 | 108 |
| 105 | Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. <i>Arthritis Research and Therapy</i> , 2014, 16, R56. | 3.5 | 108 |
| 106 | Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 234-240. | 0.9 | 107 |
| 107 | Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 778-786. | 0.9 | 104 |
| 108 | Multimorbidity and rheumatic conditions "enhancing the concept of comorbidity. <i>Nature Reviews Rheumatology</i> , 2014, 10, 252-256. | 8.0 | 103 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Therapeutic blockade of TNF in patients with SLE—Promising or crazy?. <i>Autoimmunity Reviews</i> , 2012, 11, 321-325. | 5.8 | 102 |
| 110 | Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 482-492. | 0.9 | 102 |
| 111 | Interleukin-6: a new therapeutic target. <i>Arthritis Research and Therapy</i> , 2006, 8, S5. | 3.5 | 101 |
| 112 | Alterations of dendritic cells in systemic lupus erythematosus: Phenotypic and functional deficiencies. <i>Arthritis and Rheumatism</i> , 2001, 44, 856-865. | 6.7 | 98 |
| 113 | Forget personalised medicine and focus on abating disease activity. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 3-6. | 0.9 | 98 |
| 114 | Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 490-498. | 0.9 | 98 |
| 115 | 2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021, 8, e000538. | 2.7 | 97 |
| 116 | Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1058-1064. | 0.9 | 95 |
| 117 | Clocking in: chronobiology in rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2015, 11, 349-356. | 8.0 | 91 |
| 118 | Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration. <i>Arthritis Care and Research</i> , 2018, 70, 571-581. | 3.4 | 91 |
| 119 | EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1628-1639. | 0.9 | 89 |
| 120 | Validating the International Classification of Functioning, Disability and Health Comprehensive Core Set for Rheumatoid Arthritis from the patient perspective: A qualitative study. <i>Arthritis and Rheumatism</i> , 2005, 53, 431-439. | 6.7 | 88 |
| 121 | The pathogenesis of rheumatoid arthritis: new insights from old clinical data?. <i>Nature Reviews Rheumatology</i> , 2012, 8, 235-243. | 8.0 | 86 |
| 122 | Tenosynovitis and osteoclast formation as the initial preclinical changes in a murine model of inflammatory arthritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 79-88. | 6.7 | 84 |
| 123 | Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. <i>Journal of Rheumatology</i> , 2002, 29, 1631-8. | 2.0 | 83 |
| 124 | Concepts important to patients with psoriatic arthritis are not adequately covered by standard measures of functioning. <i>Arthritis and Rheumatism</i> , 2007, 57, 487-494. | 6.7 | 82 |
| 125 | Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1190-1196. | 0.9 | 82 |
| 126 | Development of patient-centred standards of care for rheumatoid arthritis in Europe: the eumusc.net project. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 902-905. | 0.9 | 82 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 127 | Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 583-589. | 0.9 | 80 |
| 128 | Superior efficacy of combination therapy for rheumatoid arthritis: Fact or fiction?. <i>Arthritis and Rheumatism</i> , 2005, 52, 2975-2983. | 6.7 | 77 |
| 129 | Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor. <i>Journal of Experimental Medicine</i> , 2016, 213, 1937-1950. | 8.5 | 75 |
| 130 | Therapeutic strategies in early rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 163-177. | 3.3 | 74 |
| 131 | The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs. <i>Rheumatology</i> , 2015, 54, 2076-2084. | 1.9 | 74 |
| 132 | Evidence for predictive validity of remission on long-term outcome in rheumatoid arthritis: A systematic review. <i>Arthritis Care and Research</i> , 2010, 62, 108-117. | 3.4 | 73 |
| 133 | Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials. <i>Arthritis Research and Therapy</i> , 2015, 17, 229. | 3.5 | 73 |
| 134 | Activation of Fas inhibits heat-induced activation of HSF1 and up-regulation of hsp70. <i>FASEB Journal</i> , 1999, 13, 833-842. | 0.5 | 72 |
| 135 | Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 345-355. | 5.6 | 72 |
| 136 | Severe infections in plasmapheresis-treated systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1998, 41, 414-420. | 6.7 | 71 |
| 137 | The patient perspective on remission in rheumatoid arthritis: "You've got limits, but you're back to being you again". <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1004-1010. | 0.9 | 71 |
| 138 | Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. <i>Nature Reviews Rheumatology</i> , 2016, 12, 743-750. | 8.0 | 71 |
| 139 | Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 335-343. | 0.9 | 71 |
| 140 | Characterization of Autoreactive T Cells to the Autoantigens Heterogeneous Nuclear Ribonucleoprotein A2 (RA33) and Filaggrin in Patients with Rheumatoid Arthritis. <i>Journal of Immunology</i> , 2002, 169, 1068-1076. | 0.8 | 70 |
| 141 | The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?. <i>Arthritis Research and Therapy</i> , 2008, 10, 208. | 3.5 | 69 |
| 142 | Cytokines as Therapeutic Targets: Advances and Limitations. <i>Immunity</i> , 2008, 28, 440-444. | 14.3 | 69 |
| 143 | Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 875-880. | 0.9 | 69 |
| 144 | Regulatory T cell-deficient scurfy mice develop systemic autoimmune features resembling lupus-like disease. <i>Arthritis Research and Therapy</i> , 2015, 17, 35. | 3.5 | 68 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Development of patient-centred standards of care for osteoarthritis in Europe: the eumusc.net-project. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1145-1149. | 0.9 | 68 |
| 146 | Pro-Inflammatory Cytokines in Rheumatoid Arthritis: Pathogenetic and Therapeutic Aspects. <i>Clinical Reviews in Allergy and Immunology</i> , 2005, 28, 239-248. | 6.5 | 67 |
| 147 | Era of biosimilars in rheumatology: reshaping the healthcare environment. <i>RMD Open</i> , 2019, 5, e000900. | 3.8 | 67 |
| 148 | Measuring functioning in patients with hand osteoarthritis—content comparison of questionnaires based on the International Classification of Functioning, Disability and Health (ICF). <i>Rheumatology</i> , 2006, 45, 1534-1541. | 1.9 | 66 |
| 149 | Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 171-178. | 0.9 | 66 |
| 150 | Non-classical monocytes as mediators of tissue destruction in arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1490-1497. | 0.9 | 65 |
| 151 | I Have Mastered the Challenge of Living With a Chronic Disease: Life Stories of People With Rheumatoid Arthritis. <i>Qualitative Health Research</i> , 2008, 18, 658-669. | 2.1 | 64 |
| 152 | Reporting of long-term extension studies: lack of consistency calls for consensus. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 886-890. | 0.9 | 64 |
| 153 | Criteria for early rheumatoid arthritis: From Bayes' law revisited to new thoughts on pathogenesis. <i>Arthritis and Rheumatism</i> , 2002, 46, 1155-1159. | 6.7 | 63 |
| 154 | Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1631-1640. | 0.9 | 63 |
| 155 | Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1479-1485. | 0.9 | 63 |
| 156 | mTOR Senses Environmental Cues to Shape the Fibroblast-like Synoviocyte Response to Inflammation. <i>Cell Reports</i> , 2018, 23, 2157-2167. | 6.4 | 62 |
| 157 | Risk profiling for a refractory course of rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 211-217. | 3.4 | 62 |
| 158 | Concepts important to persons with systemic lupus erythematosus and their coverage by standard measures of disease activity and health status. <i>Arthritis and Rheumatism</i> , 2007, 57, 1287-1295. | 6.7 | 61 |
| 159 | The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 855-861. | 0.9 | 61 |
| 160 | Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1290-1297. | 0.9 | 61 |
| 161 | Infliximab: 12 years of experience. <i>Arthritis Research and Therapy</i> , 2011, 13, S2. | 3.5 | 60 |
| 162 | Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 201-208. | 0.9 | 59 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 163 | Development of a multimorbidity index: Impact on quality of life using a rheumatoid arthritis cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 167-173. | 3.4 | 58 |
| 164 | Safety and efficacy of biosimilars in oncology. <i>Lancet Oncology</i> , The, 2016, 17, e502-e509. | 10.7 | 58 |
| 165 | Reference sera for antinuclear antibodies. II. Further definition of antibody specificities in international antinuclear antibody reference sera by immunofluorescence and western blotting. <i>Arthritis and Rheumatism</i> , 1997, 40, 413-418. | 6.7 | 56 |
| 166 | The concurrence of rheumatoid arthritis and limited systemic sclerosis: Clinical and serologic characteristics of an overlap syndrome. <i>Arthritis and Rheumatism</i> , 1998, 41, 1938-1945. | 6.7 | 56 |
| 167 | Developments in the clinical understanding of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2009, 11, 204. | 3.5 | 56 |
| 168 | Sonographic Joint Assessment in Rheumatoid Arthritis: Associations With Clinical Joint Assessment During a State of Remission. <i>Arthritis and Rheumatism</i> , 2013, 65, 2005-2014. | 6.7 | 56 |
| 169 | Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1156-1162. | 0.9 | 56 |
| 170 | Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1310-1319. | 0.9 | 56 |
| 171 | Rheumatoid arthritis near remission: clinical rather than laboratory inflammation is associated with radiographic progression. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1975-1980. | 0.9 | 54 |
| 172 | A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1598-1602. | 0.9 | 54 |
| 173 | Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1671-1679. | 0.9 | 53 |
| 174 | Relationship between disease activity indices and their individual components and radiographic progression in RA: a systematic literature review. <i>Rheumatology</i> , 2015, 54, 994-1007. | 1.9 | 51 |
| 175 | Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 634-640. | 0.9 | 51 |
| 176 | Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. <i>Arthritis Research and Therapy</i> , 2015, 17, 14. | 3.5 | 49 |
| 177 | Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results. <i>Rheumatology</i> , 2017, 56, 1771-1779. | 1.9 | 49 |
| 178 | Determination of Autoantibody Isotypes Increases the Sensitivity of Serodiagnostics in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2018, 9, 876. | 4.8 | 49 |
| 179 | IRF1 is critical for the TNF-driven interferon response in rheumatoid fibroblast-like synoviocytes. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-11. | 7.7 | 49 |
| 180 | Tocilizumab. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 273-274. | 46.4 | 48 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. <i>RMD Open</i> , 2020, 6, e001095. | 3.8 | 48 |
| 182 | Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 575-578. | 0.9 | 47 |
| 183 | Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2016, 55, 710-720. | 1.9 | 47 |
| 184 | Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, 900-908. | 1.9 | 47 |
| 185 | The need for new classification criteria for rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2005, 52, 3333-3336. | 6.7 | 46 |
| 186 | Development of a new occupational balance-questionnaire: incorporating the perspectives of patients and healthy people in the design of a self-reported occupational balance outcome instrument. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 45. | 2.4 | 45 |
| 187 | Treat-to-target as an approach in inflammatory arthritis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 297-302. | 4.3 | 45 |
| 188 | Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets. <i>Nature Reviews Rheumatology</i> , 2019, 15, 633-634. | 8.0 | 45 |
| 189 | Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. <i>Journal of Rheumatology</i> , 2019, 46, 721-726. | 2.0 | 45 |
| 190 | Tumor necrosis factor- α inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor- α driven model of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2013, 65, 608-617. | 6.7 | 44 |
| 191 | Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 241-244. | 0.9 | 44 |
| 192 | Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials. <i>Modern Rheumatology</i> , 2020, 30, 36-43. | 1.8 | 44 |
| 193 | Mechanisms of tissue damage in arthritis. <i>Seminars in Immunopathology</i> , 2014, 36, 531-540. | 6.1 | 43 |
| 194 | MicroRNA-146a governs fibroblast activation and joint pathology in arthritis. <i>Journal of Autoimmunity</i> , 2017, 82, 74-84. | 6.5 | 43 |
| 195 | Impact of Treatment-Related Beliefs on Medication Adherence in Immune-Mediated Inflammatory Diseases: Results of the Global ALIGN Study. <i>Advances in Therapy</i> , 2017, 34, 91-108. | 2.9 | 43 |
| 196 | Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 687-694. | 0.9 | 43 |
| 197 | Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 445-452. | 0.9 | 42 |
| 198 | Predictors, Risk Factors, and Incidence Rates of Psoriatic Arthritis Development in Psoriasis Patients: A Systematic Literature Review and Meta-Analysis. <i>Rheumatology and Therapy</i> , 2021, 8, 1519-1534. | 2.3 | 42 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 199 | Loss of phosphatase and tensin homolog (PTEN) in myeloid cells controls inflammatory bone destruction by regulating the osteoclastogenic potential of myeloid cells. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 227-233. | 0.9 | 41 |
| 200 | Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 838-844. | 0.9 | 41 |
| 201 | Implementation of Treat-to-Target in Rheumatoid Arthritis Through a Learning Collaborative: Results of a Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , 2017, 69, 1374-1380. | 5.6 | 40 |
| 202 | Treatment Patterns of Multimorbid Patients with Rheumatoid Arthritis: Results from an International Cross-sectional Study. <i>Journal of Rheumatology</i> , 2015, 42, 1099-1104. | 2.0 | 39 |
| 203 | Biosimilar safety factors in clinical practice. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, S9-S15. | 3.4 | 39 |
| 204 | Preservation of cartilage and bone architecture is the most important aspect for maintaining functionality in longstanding experimental arthritis. <i>DMM Disease Models and Mechanisms</i> , 2016, 9, 1329-1338. | 2.4 | 39 |
| 205 | Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria. <i>Arthritis and Rheumatology</i> , 2017, 69, 728-734. | 5.6 | 39 |
| 206 | Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis. <i>RMD Open</i> , 2017, 3, e000546. | 3.8 | 39 |
| 207 | Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries. <i>Arthritis Care and Research</i> , 2020, 72, 1772-1779. | 3.4 | 39 |
| 208 | When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS). <i>RMD Open</i> , 2016, 2, e000221. | 3.8 | 38 |
| 209 | The effects of structural damage on functional disability in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 2038-2045. | 0.9 | 38 |
| 210 | Health determining concepts important to people with Crohn's disease and their coverage by patient-reported outcomes of health and wellbeing. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 45-55. | 1.3 | 37 |
| 211 | Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE). <i>Arthritis Research and Therapy</i> , 2015, 17, 157. | 3.5 | 37 |
| 212 | Predictors for influenza vaccine acceptance among patients with inflammatory rheumatic diseases. <i>Vaccine</i> , 2018, 36, 4875-4879. | 3.8 | 37 |
| 213 | Environmental arginine controls multinuclear giant cell metabolism and formation. <i>Nature Communications</i> , 2020, 11, 431. | 12.8 | 37 |
| 214 | European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781. | 0.9 | 37 |
| 215 | Systemic Lupus Erythematosus: Delineation of Subpopulations by Clinical, Serologic, and T Cell Subset Analysis. <i>American Journal of the Medical Sciences</i> , 1985, 289, 139-147. | 1.1 | 36 |
| 216 | Developing an effective treatment algorithm for rheumatoid arthritis. <i>Rheumatology</i> , 2012, 51, v48-v54. | 1.9 | 36 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | Application of the 2010 ACR/EULAR classification criteria in patients with very early inflammatory arthritis: analysis of sensitivity, specificity and predictive values in the SAVE study cohort. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1335-1341. | 0.9 | 36 |
| 218 | Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 963-969. | 0.9 | 36 |
| 219 | New GRAPPA and EULAR recommendations for the management of psoriatic arthritis. <i>Rheumatology</i> , 2017, 56, kew390. | 1.9 | 36 |
| 220 | Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. <i>RMD Open</i> , 2020, 6, e001374. | 3.8 | 36 |
| 221 | Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 872-878. | 0.9 | 36 |
| 222 | Patient global assessment in psoriatic arthritis – what does it mean? An analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study. <i>Joint Bone Spine</i> , 2016, 83, 335-340. | 1.6 | 35 |
| 223 | Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. <i>Lupus Science and Medicine</i> , 2020, 7, e000424. | 2.7 | 35 |
| 224 | Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1333-1339. | 0.9 | 35 |
| 225 | Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2007, 34, 1465-74. | 2.0 | 34 |
| 226 | Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1609-1615. | 0.9 | 33 |
| 227 | I Would Never Take Preventive Medication! Perspectives and Information Needs of People Who Underwent Predictive Tests for Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2020, 72, 360-368. | 3.4 | 33 |
| 228 | Activity assessments in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2008, 20, 306-313. | 4.3 | 32 |
| 229 | Monitoring rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2011, 23, 252-258. | 4.3 | 32 |
| 230 | Perceptions of risk and predictive testing held by the first-degree relatives of patients with rheumatoid arthritis in England, Austria and Germany: a qualitative study. <i>BMJ Open</i> , 2016, 6, e010555. | 1.9 | 32 |
| 231 | Nicotinic acetylcholine receptors modulate osteoclastogenesis. <i>Arthritis Research and Therapy</i> , 2016, 18, 63. | 3.5 | 32 |
| 232 | Targeted inhibition of Janus kinases abates interferon gamma-induced invasive behaviour of fibroblast-like synoviocytes. <i>Rheumatology</i> , 2018, 57, 572-577. | 1.9 | 32 |
| 233 | Interferon signals and monocytic sensitization of the interferon- γ signaling pathway in the peripheral blood of patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 400-408. | 6.7 | 31 |
| 234 | Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1567-1570. | 0.9 | 31 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 235 | Back to the future: forget ultrasound and focus on clinical assessment in rheumatoid arthritis management. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 18-20. | 0.9 | 31 |
| 236 | Treat to Target in Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 477-485. | 1.9 | 31 |
| 237 | Histone deacetylase 1 (HDAC1): A key player of T cell-mediated arthritis. <i>Journal of Autoimmunity</i> , 2020, 108, 102379. | 6.5 | 31 |
| 238 | MicroRNA 155-deficiency leads to decreased autoantibody levels and reduced severity of nephritis and pneumonitis in pristane-induced lupus. <i>PLoS ONE</i> , 2017, 12, e0181015. | 2.5 | 30 |
| 239 | Response to: "Comment on: EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update" by Gossec et al. by Wei et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e139-e139. | 0.9 | 30 |
| 240 | Greetings from the editor. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 677-678. | 0.9 | 30 |
| 241 | Disease activity and response assessment in psoriatic arthritis using the Disease Activity index for Psoriatic Arthritis (DAPSA). A brief review. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S48-50. | 0.8 | 30 |
| 242 | Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1811-1818. | 0.9 | 29 |
| 243 | Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study. <i>RMD Open</i> , 2018, 4, e000564. | 3.8 | 29 |
| 244 | Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial. <i>Arthritis Research and Therapy</i> , 2018, 20, 8. | 3.5 | 29 |
| 245 | Clinical and immunological aspects of autoantibodies to RA33/hnRNP-A/B proteins ? A link between RA, SLE and MCTD. <i>Molecular Biology Reports</i> , 1996, 23, 167-171. | 2.3 | 28 |
| 246 | Rheumatoid arthritis is more than cytokines: Autoimmunity and rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2001, 44, 2218-2220. | 6.7 | 28 |
| 247 | When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1497-1498. | 0.9 | 28 |
| 248 | Definitions of occupational balance and their coverage by instruments. <i>British Journal of Occupational Therapy</i> , 2015, 78, 4-15. | 0.9 | 28 |
| 249 | Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial. <i>RMD Open</i> , 2019, 5, e001040. | 3.8 | 28 |
| 250 | Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 884-890. | 0.9 | 28 |
| 251 | Insights into the treatment of rheumatoid arthritis: A paradigm in medicine. <i>Journal of Autoimmunity</i> , 2020, 110, 102425. | 6.5 | 27 |
| 252 | Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1268-1271. | 0.9 | 26 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 253 | Barriers to treatment adjustment within a treat to target strategy in rheumatoid arthritis: a secondary analysis of the TRACTION trial. <i>Rheumatology</i> , 2018, 57, 1933-1937. | 1.9 | 26 |
| 254 | Contributions of ultrasound beyond clinical data in assessing inflammatory disease activity in rheumatoid arthritis: current insights and future prospects. <i>Rheumatology</i> , 2014, 53, 2136-2142. | 1.9 | 25 |
| 255 | Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 276-284. | 3.4 | 25 |
| 256 | Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 7-12. | 0.9 | 24 |
| 257 | Phosphatase and tensin homolog (PTEN) in antigen-presenting cells controls Th17-mediated autoimmune arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 230. | 3.5 | 24 |
| 258 | Different Rating of Global Rheumatoid Arthritis Disease Activity in Rheumatoid Arthritis Patients With Multiple Morbidities. <i>Arthritis and Rheumatology</i> , 2017, 69, 720-727. | 5.6 | 24 |
| 259 | MicroRNA-155 Controls T Helper Cell Activation During Viral Infection. <i>Frontiers in Immunology</i> , 2019, 10, 1367. | 4.8 | 24 |
| 260 | The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 164. | 3.5 | 24 |
| 261 | The assessment of disease activity in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, S18-27. | 0.8 | 24 |
| 262 | Information technology in rheumatology. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 1. | 0.8 | 24 |
| 263 | Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2015, 17, 203. | 3.5 | 23 |
| 264 | Quality indicators in rheumatoid arthritis: results from the METEOR database. <i>Rheumatology</i> , 2015, 54, 1630-1639. | 1.9 | 23 |
| 265 | Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1566-1572. | 0.9 | 23 |
| 266 | Challenges of predicting treatment response in patients with rheumatoid arthritis. <i>Nature Clinical Practice Rheumatology</i> , 2005, 1, 62-63. | 3.2 | 22 |
| 267 | Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure. <i>Arthritis Research and Therapy</i> , 2006, 8, R46. | 3.5 | 22 |
| 268 | Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 289-292. | 0.9 | 22 |
| 269 | Functional consultation and exercises improve grip strength in osteoarthritis of the hand – a randomised controlled trial. <i>Arthritis Research and Therapy</i> , 2018, 20, 253. | 3.5 | 22 |
| 270 | Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 709-718. | 3.4 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 271 | Treat-to-target: rationale and strategies. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S2-6. | 0.8 | 22 |
| 272 | Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2020, 59, 153-164. | 1.9 | 21 |
| 273 | Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study. <i>Rheumatology and Therapy</i> , 2020, 7, 1021-1035. | 2.3 | 21 |
| 274 | Interleukin 6 is not a crucial regulator in an animal model of tumour necrosis factor-mediated bilateral sacroiliitis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1403-1406. | 0.9 | 20 |
| 275 | A Combination of CD28 (rs1980422) and IRF5 (rs10488631) Polymorphisms Is Associated with Seropositivity in Rheumatoid Arthritis: A Case Control Study. <i>PLoS ONE</i> , 2016, 11, e0153316. | 2.5 | 20 |
| 276 | Remission in Rheumatoid Arthritis: Working Toward Incorporation of the Patient Perspective at OMERACT 12. <i>Journal of Rheumatology</i> , 2016, 43, 203-207. | 2.0 | 20 |
| 277 | FOXO3 is involved in the tumor necrosis factor-driven inflammatory response in fibroblast-like synoviocytes. <i>Laboratory Investigation</i> , 2019, 99, 648-658. | 3.7 | 20 |
| 278 | Rheumatoid arthritis disease activity and the risk of aseptic arthroplasty loosening. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 245-251. | 3.4 | 20 |
| 279 | microRNA-146a controls age-related bone loss. <i>Aging Cell</i> , 2020, 19, e13244. | 6.7 | 20 |
| 280 | Rheumatoid arthritis Primer " behind the scenes. <i>Nature Reviews Disease Primers</i> , 2020, 6, 32. | 30.5 | 20 |
| 281 | Treatment of psoriatic arthritis: management recommendations. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S73-7. | 0.8 | 20 |
| 282 | CD55 deposited on synovial collagen fibers protects from immune complex-mediated arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 6. | 3.5 | 19 |
| 283 | Implementation of treat-to-target in rheumatoid arthritis through a Learning Collaborative: Rationale and design of the TRACTION trial. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 81-87. | 3.4 | 18 |
| 284 | Relation of Nailfold Capillaries and Autoantibodies to Mortality in Patients With Raynaud Phenomenon. <i>Circulation</i> , 2016, 133, 509-517. | 1.6 | 18 |
| 285 | How are enthesitis, dactylitis and nail involvement measured and reported in recent clinical trials of psoriatic arthritis? A systematic literature review. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 782-783. | 0.9 | 18 |
| 286 | Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. <i>Arthritis Research and Therapy</i> , 2018, 20, 174. | 3.5 | 18 |
| 287 | Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial. <i>Rheumatology and Therapy</i> , 2019, 6, 409-419. | 2.3 | 18 |
| 288 | Greetings from the editor 2019. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1-2. | 0.9 | 18 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 289 | Greetings from the editor 2020. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1-2. | 0.9 | 18 |
| 290 | The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy. <i>Journal of rheumatology Supplement, The</i> , 2004, 71, 13-20. | 2.2 | 18 |
| 291 | Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 823-830. | 0.9 | 18 |
| 292 | Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 133. | 3.5 | 17 |
| 293 | Do patient-reported outcome measures cover personal factors important to people with rheumatoid arthritis? A mixed methods design using the International Classification of Functioning, Disability and Health as frame of reference. <i>Health and Quality of Life Outcomes</i> , 2015, 13, 27. | 2.4 | 17 |
| 294 | Disease activity assessment in patients with psoriatic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 401-414. | 3.3 | 17 |
| 295 | Achieving Clinical Remission for Patients With Rheumatoid Arthritis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 457. | 7.4 | 17 |
| 296 | Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1419-1428. | 0.9 | 17 |
| 297 | Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 874-882. | 0.9 | 16 |
| 298 | Therapy of systemic lupus erythematosus: a look into the future. <i>Arthritis Research</i> , 2002, 4, S25. | 2.0 | 15 |
| 299 | Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate. <i>Rheumatology</i> , 2016, 55, 1458-1465. | 1.9 | 15 |
| 300 | Clinical meaning and implications of serum hemoglobin levels in patients with rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 193-198. | 3.4 | 14 |
| 301 | Response to: "Correspondence on EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update" by Fallon et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e174-e174. | 0.9 | 14 |
| 302 | Determinants of sleep impairment in psoriatic arthritis: An observational study with 396 patients from 14 countries. <i>Joint Bone Spine</i> , 2020, 87, 449-454. | 1.6 | 14 |
| 303 | Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial. <i>Rheumatology</i> , 2021, 60, 256-262. | 1.9 | 14 |
| 304 | Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 937-943. | 0.9 | 14 |
| 305 | The American College of Rheumatology N (ACR-N) debate: Going back into the middle of the tunnel? Comment on the articles by Siegel and Zhen and by Boers. <i>Arthritis and Rheumatism</i> , 2006, 54, 377-378. | 6.7 | 13 |
| 306 | Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis. <i>RMD Open</i> , 2018, 4, e000602. | 3.8 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 307 | An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases. <i>Rheumatology</i> , 2020, 59, 1842-1852. | 1.9 | 13 |
| 308 | Greetings from the editor 2021. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1-3. | 0.9 | 13 |
| 309 | Defining remission and treatment success using the DAPSA score: response to letter by Helliwell and Coates. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e67-e67. | 0.9 | 12 |
| 310 | Initial evidence for the link between activities and health: Associations between a balance of activities, functioning and serum levels of cytokines and C-reactive protein. <i>Psychoneuroendocrinology</i> , 2016, 65, 138-148. | 2.7 | 12 |
| 311 | Analysis of gene expression in rheumatoid arthritis and related conditions offers insights into sex-bias, gene biotypes and co-expression patterns. <i>PLoS ONE</i> , 2019, 14, e0219698. | 2.5 | 12 |
| 312 | An intergenerational program based on psycho-motor activity promotes well-being and interaction between preschool children and older adults: results of a process and outcome evaluation study in Austria. <i>BMC Public Health</i> , 2019, 19, 254. | 2.9 | 12 |
| 313 | Comparing the Patient-Reported Physical Function Outcome Measures in a Real-Life International Cohort of Patients With Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 593-602. | 3.4 | 12 |
| 314 | Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study. <i>Rheumatology</i> , 2021, 60, 2256-2266. | 1.9 | 12 |
| 315 | Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects. <i>RMD Open</i> , 2021, 7, e001637. | 3.8 | 12 |
| 316 | Torque Teno Virus quantification for monitoring of immunomodulation with biologic compounds in the treatment of rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 2815-2825. | 1.9 | 12 |
| 317 | Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1755-1760. | 0.9 | 11 |
| 318 | Benefits and Sustainability of a Learning Collaborative for Implementation of Treatment Target in Rheumatoid Arthritis: Results of a Cluster-Randomized Controlled Phase Clinical Trial. <i>Arthritis Care and Research</i> , 2018, 70, 1551-1556. | 3.4 | 11 |
| 319 | Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative. <i>Journal of Rheumatology</i> , 2019, 46, 1159-1163. | 2.0 | 11 |
| 320 | EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1423-1431. | 0.9 | 11 |
| 321 | Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 115. | 3.5 | 11 |
| 322 | Chronicity of rheumatoid arthritis affects the responsiveness of physical function, but not of disease activity measures in rheumatoid arthritis clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 532-537. | 0.9 | 10 |
| 323 | CCR6 controls autoimmune but not innate immunity-driven experimental arthritis. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 5278-5285. | 3.6 | 10 |
| 324 | Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study. <i>RMD Open</i> , 2018, 4, e000773. | 3.8 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 325 | Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses. <i>Rheumatology and Therapy</i> , 2018, 5, 341-353. | 2.3 | 9 |
| 326 | Efficacy outcomes in phase 2 and phase 3 randomized controlled trials in rheumatology. <i>Nature Medicine</i> , 2020, 26, 974-980. | 30.7 | 9 |
| 327 | Response to: "Correspondence on "Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement" by Banday et al. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e105-e105. | 0.9 | 9 |
| 328 | How well can we compare different biologic agents for RA?. <i>Nature Reviews Rheumatology</i> , 2010, 6, 247-248. | 8.0 | 8 |
| 329 | Multimodal [18F]FDG PET/CT Is a Direct Readout for Inflammatory Bone Repair: A Longitudinal Study in TNF± Transgenic Mice. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 1632-1645. | 2.8 | 8 |
| 330 | Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110225. | 2.7 | 8 |
| 331 | Considerations and priorities for incorporating the patient perspective on remission in rheumatoid arthritis: An OMERACT 2020 special interest group report. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1108-1112. | 3.4 | 8 |
| 332 | OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 601-606. | 3.4 | 7 |
| 333 | Information technology concerning SDAI and CDAI. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S45-S48. | 0.8 | 7 |
| 334 | Glucocorticoid Effect on Radiographic Progression in Placebo Arms of Rheumatoid Arthritis Biologics Trials. <i>Journal of Rheumatology</i> , 2016, 43, 1024-1026. | 2.0 | 6 |
| 335 | Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials. <i>Arthritis Research and Therapy</i> , 2019, 21, 231. | 3.5 | 6 |
| 336 | FRIO193...2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , . | | 6 |
| 337 | Treatment "Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations. <i>Arthritis Care and Research</i> , 2020, 72, 814-821. | 3.4 | 6 |
| 338 | Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 643-644. | 3.4 | 6 |
| 339 | Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working group. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 242-249. | 0.9 | 6 |
| 340 | Trajectory clusters of radiographic progression in patients with rheumatoid arthritis: associations with clinical variables. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 175-183. | 0.9 | 6 |
| 341 | Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1374-1378. | 0.9 | 6 |
| 342 | Reply:. <i>Arthritis and Rheumatism</i> , 2005, 52, 4045-4047. | 6.7 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 343 | Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone. <i>RMD Open</i> , 2017, 3, e000445. | 3.8 | 5 |
| 344 | THU0078â€¦SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 7 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS. , 2019, , . | | 5 |
| 345 | Greetings from the editor 2022. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1-3. | 0.9 | 5 |
| 346 | Ten years of infliximab: Insights from clinical trials in rheumatoid arthritis. <i>European Journal of Pharmacology</i> , 2009, 623, S5-S9. | 3.5 | 4 |
| 347 | Interphalangeal Osteoarthritis Radiographic Simplified (iOARS) score: a radiographic method to detect osteoarthritis of the interphalangeal finger joints based on its histopathological alterations. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1983-1989. | 0.9 | 4 |
| 348 | Response to: â€˜2016 update of the EULAR recommendations for the management of rheumatoid arthritis: no utopia for patients in low/middle-income countries?â€™ by Misra et al. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e48-e48. | 0.9 | 4 |
| 349 | The new editor greets you. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1636-1636. | 0.9 | 4 |
| 350 | Contribution of Genetic Factors to Lower DHEAS in Patients with Rheumatoid Arthritis. <i>Cellular and Molecular Neurobiology</i> , 2018, 38, 379-383. | 3.3 | 4 |
| 351 | Considering new lessons about the use of IL-6 inhibitors in arthritis. <i>Considerations in Medicine</i> , 2018, 2, 7-11. | 0.0 | 4 |
| 352 | Effects of a brief workplace-centered consultation for employees with musculoskeletal pain on health outcomes: a prospective cohort study. <i>Scientific Reports</i> , 2019, 9, 5867. | 3.3 | 4 |
| 353 | 185â€¦Baricitinib-associated changes in type I interferon gene signature during a 24-week phase 2 clinical SLE trial. , 2019, , . | | 4 |
| 354 | Whatâ€¦influences patientsâ€™ opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international study. <i>Rheumatology</i> , 2021, 60, 5292-5299. | 1.9 | 4 |
| 355 | What is the place of recently approved T cell-targeted and B cell-targeted therapies in the treatment of rheumatoid arthritis? Lessons from global clinical trials. <i>Journal of rheumatology Supplement</i> , The, 2007, 79, 15-20. | 2.2 | 4 |
| 356 | Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 622-631. | 0.9 | 4 |
| 357 | Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2022, 49, 694-699. | 2.0 | 4 |
| 358 | Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries. <i>RMD Open</i> , 2022, 8, e002031. | 3.8 | 4 |
| 359 | Expanding the frontiers of therapy. <i>Arthritis Research and Therapy</i> , 2006, 8, S1. | 3.5 | 3 |
| 360 | Strengths and limitations of a systematic review on DMARDs for rheumatoid arthritis. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 296-297. | 3.2 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 361 | Opportunities and challenges in rheumatology research in Central Europe. <i>Arthritis Research and Therapy</i> , 2017, 19, 196. | 3.5 | 3 |
| 362 | Targeting IL-6: A review of data. <i>Considerations in Medicine</i> , 2018, 2, 12-18. | 0.0 | 3 |
| 363 | e48â€fEffects of baricitinib on haematological laboratory parameters in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, . | 1.9 | 3 |
| 364 | To DAPSA or not to DAPSA? That is not the question. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e61-e61. | 0.9 | 3 |
| 365 | OP0007â€f...HIGH BODY MASS INDEX (BMI) IN PSORIATIC ARTHRITIS (PSA) IS ASSOCIATED WITH HIGHER DISEASE ACTIVITY IN JOINTS AND SKIN, IMPAIRED QUALITY OF LIFE AND MORE DISABILITY: RESULTS FROM THE PSABIO STUDY. , 2019, , . | | 3 |
| 366 | THU0193â€f...EFFICACY OF TOFACITINIB MONOTHERAPY, TOFACITINIB WITH METHOTREXATE AND ADALIMUMAB WITH METHOTREXATE IN PATIENTS WITH EARLY (&%2 YEARS) VS ESTABLISHED (>2 YEARS) RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF DATA FROM ORAL STRATEGY. , 2019, , . | | 3 |
| 367 | Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis. <i>RMD Open</i> , 2020, 6, e001096. | 3.8 | 3 |
| 368 | Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2021, 384, 83-84. | 27.0 | 3 |
| 369 | Alterations of dendritic cells in systemic lupus erythematosus: Phenotypic and functional deficiencies. <i>Arthritis and Rheumatism</i> , 2001, 44, 856-865. | 6.7 | 3 |
| 370 | Prevalence and validity of ACR/EULAR remission in four European early rheumatoid arthritis cohorts. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 362-370. | 0.8 | 3 |
| 371 | Role of clinical and biochemical inflammation in structural progression of patients with psoriatic arthritis. <i>RMD Open</i> , 2021, 7, e002038. | 3.8 | 3 |
| 372 | Analysis of combined deficiency of interleukin-1 and -6 versus single deficiencies in TNF-mediated arthritis and systemic bone loss. <i>Bone and Joint Research</i> , 2022, 11, 484-493. | 3.6 | 3 |
| 373 | Response to: â€fEvidence for treating rheumatoid arthritis to target: results of a systematic literature search updateâ€™ by Goswami<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e36-e36. | 0.9 | 2 |
| 374 | 245â€fRemission/low disease activity is an achievable treatment target in psoriatic arthritis (PsA): results from a routine care European cohort of PsA patients treated with ustekinumab or TNF inhibitors. <i>Rheumatology</i> , 2019, 58, . | 1.9 | 2 |
| 375 | Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 188. | 3.5 | 2 |
| 376 | Greetings from the editor. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 677-678. | 0.9 | 2 |
| 377 | Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy. <i>Arthritis Research and Therapy</i> , 2021, 23, 220. | 3.5 | 2 |
| 378 | Severe infections in plasmapheresisâ€ftreated systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1998, 41, 414-420. | 6.7 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 379 | Response to: Where are the women â€˜Heroes and Pillars of Rheumatologyâ€™?. Annals of the Rheumatic Diseases, 2023, 82, e200-e200. | 0.9 | 2 |
| 380 | Reflections on a contemporary European tragedy. Annals of the Rheumatic Diseases, 2022, 81, 747-748. | 0.9 | 2 |
| 381 | Greetings from the editor. Annals of the Rheumatic Diseases, 2022, 81, 748-750. | 0.9 | 2 |
| 382 | On publication policy, combination therapy, and the European League Against Rheumatism recommendations for the management of rheumatoid arthritis: Comment on the article by Graudal et al. Arthritis and Rheumatism, 2011, 63, 3182-3185. | 6.7 | 1 |
| 383 | Nicotinic acetylcholine receptor activation completely blocks osteoclastogenesis by interfering with osteoclast precursor differentiation in vitro. Annals of the Rheumatic Diseases, 2011, 70, A74-A75. | 0.9 | 1 |
| 384 | A1.82â€¦Limited role of microrna 155 innate immunity dependent arthritis. Annals of the Rheumatic Diseases, 2014, 73, A36.1-A36. | 0.9 | 1 |
| 385 | Response to â€˜Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritisâ€™. Arthritis Research and Therapy, 2015, 17, 166. | 3.5 | 1 |
| 386 | 078â€¦Efficacy and Safety of Baricitinib in Patients with Active Rheumatoid Arthritis and Inadequate Response to Tumour Necrosis Factor Inhibitors: Summary Results from the 24-Week Phase III RA-Beacon Study. Rheumatology, 0, , . | 1.9 | 1 |
| 387 | 02.06â€¦Ccr6 modulates severity of arthritis in T cell dependent manner. , 2017, , . | | 1 |
| 388 | Response to: â€˜The GRAPPA-OMERACT initiative to standardise outcomes in Psoriatic Arthritis clinical trials and longitudinal observational studiesâ€™ by Tillet <i>et al</i>. Annals of the Rheumatic Diseases, 2018, 77, e24-e24. | 0.9 | 1 |
| 389 | 219â€¦Safety summary results of baricitinib focusing on serious infections events and preselected comorbidities. Rheumatology, 2018, 57, . | 1.9 | 1 |
| 390 | Does Triple Conventional Synthetic Disease-Modifying Antirheumatic Drug Therapy Improve upon Methotrexate as the Initial Treatment of Choice for a Rheumatoid Arthritis Patient?. Rheumatic Disease Clinics of North America, 2019, 45, 315-324. | 1.9 | 1 |
| 391 | 074â€¦Summary of indirect comparison to evaluate efficacy of baricitinib with targeted synthetic and biologic disease anti-rheumatic drugs in patients with rheumatoid arthritis. Rheumatology, 2019, 58, . | 1.9 | 1 |
| 392 | FRI0164â€¦INCIDENCE RATE AND CHARACTERIZATION OF HERPES ZOSTER IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: AN UPDATE FROM BARICITINIB CLINICAL STUDIES. , 2019, , . | | 1 |
| 393 | Hand X-ray examination in two planes is not required for radiographic assessment of hand osteoarthritis. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2093493. | 2.7 | 1 |
| 394 | Response to: â€˜Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritisâ€™ by Bugatti<i>et al</i>. Annals of the Rheumatic Diseases, 2022, 81, e56-e56. | 0.9 | 1 |
| 395 | Doubtful swelling on clinical examination reflects synovitis in rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2093348. | 2.7 | 1 |
| 396 | Is Methotrexate as Efficacious as Etanercept in Psoriatic Arthritis Patients? Comment on the Article by Mease et al. Arthritis and Rheumatology, 2020, 72, 1227-1229. | 5.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 397 | Response to: "Correspondence on "Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study" by Charles. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e110-e110. | 0.9 | 1 |
| 398 | 009" Safety profile of baricitinib for the treatment of RA up to 8.4 years: an updated integrated safety analysis. <i>Rheumatology</i> , 2021, 60, . | 1.9 | 1 |
| 399 | A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities: I. Precision, sensitivity, and specificity. , 1999, 42, 455. | | 1 |
| 400 | Impact of Treatment-Related Beliefs on Medication Adherence in Immune-Mediated Inflammatory Diseases: Results of the Global ALIGN Study. , 2017, 34, 91. | | 1 |
| 401 | Implementing a "Treat-to-Target" Approach for Rheumatoid Arthritis During the COVID-19 Pandemic: Results of a Virtual Learning Collaborative Program. <i>Arthritis Care and Research</i> , 2022, 74, 572-578. | 3.4 | 1 |
| 402 | Objectives and strategies for rheumatoid arthritis therapy: yesterday vs. today. <i>Drugs of Today</i> , 2003, 39 Suppl B, 3-8. | 1.1 | 1 |
| 403 | The eumusc.net standards of care for rheumatoid arthritis: importance and current implementation according to patients and healthcare providers in the Netherlands. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 275-283. | 0.8 | 1 |
| 404 | P196" Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 9.3 years: an updated integrated safety analysis. <i>Rheumatology</i> , 2022, 61, . | 1.9 | 1 |
| 405 | The challenge of following process, damage, and function in patients with rheumatoid arthritis in clinical care. <i>Current Rheumatology Reports</i> , 2003, 5, 336-340. | 4.7 | 0 |
| 406 | Sensitisation of the IFN-Stat1-signalling-pathway in rheumatoid arthritis monocytes. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A15-A16. | 0.9 | 0 |
| 407 | Combined depletion of interleukin 1 and interleukin 6 does not exceed single depletion of interleukin 1 in TNF mediated arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A72-A72. | 0.9 | 0 |
| 408 | Multi-targeted kinase inhibitor PKC412 diminishes osteoclastogenesis and counteracts osteoclast function in vitro. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A81-A81. | 0.9 | 0 |
| 409 | Micro-RNA 155 controls the pathogenesis of autoimmune arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A79-A80. | 0.9 | 0 |
| 410 | Real time in vivo analysis of granulomonocytic cell migration in the collagen induced arthritis model. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A73.2-A73. | 0.9 | 0 |
| 411 | Muscle wasting in hTNFtg mice, an animal model for rheumatoid arthritis, due to increased cathepsin L expression. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A45.1-A45. | 0.9 | 0 |
| 412 | Sustained PI3-kinase activity in myeloid cells enhances osteoclastogenesis and augments local bone destruction. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A67.1-A67. | 0.9 | 0 |
| 413 | A8.7" Functional Impairment in an Animal Model for Rheumatoid Arthritis Assessed as Changes in Gait is Due to Joint Destruction But Not Synovial Inflammation Per Se. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A59.2-A60. | 0.9 | 0 |
| 414 | A2.19" The Role of microRNA 155 in Innate Immunity and Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A11.2-A11. | 0.9 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 415 | A9.7â€¦Loss of PTEN in Myeloid Cells Controls Inflammatory Bone Destruction by Regulating the Osteoclastogenic Potential of Myeloid Cells. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A66.3-A67. | 0.9 | 0 |
| 416 | A4.6â€¦Effects of Cholic Acid and its Derivatives in Experimental Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A25.2-A26. | 0.9 | 0 |
| 417 | A1.81â€¦Mincle is not essential in T-cell independent arthritis models. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A35.3-A36. | 0.9 | 0 |
| 418 | A8.30â€¦Analysis of monocyte-fibroblast interaction in 3D synovial micromass tissue cultures. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A88.1-A88. | 0.9 | 0 |
| 419 | Advances in targeted therapy. <i>Rheumatology</i> , 2016, 55, ii1-ii2. | 1.9 | 0 |
| 420 | Title is missing!. <i>Japanese Journal of Clinical Immunology</i> , 2016, 39, 388a-388a. | 0.0 | 0 |
| 421 | Response to: â€œThe time has come to revisit alternative interpretations of data underlying the EULAR management recommendations for rheumatoid arthritisâ€™ by PiriÅ <i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e50-e50. | 0.9 | 0 |
| 422 | 04.05â€¦The metabolic checkpoint kinase mtor regulates the rheumatoid mesenchymal tissue response to inflammation. , 2017, , . | | 0 |
| 423 | 08.28â€¦The prognostic value of iga autoantibodies (rheumatoid factor and acpa) for prediction of the therapeutic response to anti-tnf therapy in patients with rheumatoid arthritis. , 2017, , . | | 0 |
| 424 | 01.11â€¦Resident non-classical monocytes are critically important for tissue destruction in arthritis. , 2017, , . | | 0 |
| 425 | 04.13â€¦The transcription factor foxo3 differentially regulates the expression of proinflammatory genes in rheumatoid fibroblast-like synoviocytes. , 2017, , . | | 0 |
| 426 | 04.15â€¦Resolution of systemic inflammatory processes and regeneration of inflammation-driven bone damage upon tnf blockade as monitored by in vivo multimodal pet-ct imaging in tnf driven experimental arthritis. , 2017, , . | | 0 |
| 427 | 04.07â€¦Microrna-146a controls local bone destruction by regulating fibroblast induced osteoclastogenesis in inflammatory arthritis. , 2017, , . | | 0 |
| 428 | 226â€¦Summary of baricitinib effect on patient-reported outcomes (PROs) in methotrexate-inadequate responder patient population. <i>Rheumatology</i> , 2018, 57, . | 1.9 | 0 |
| 429 | 233â€¦Durability, maintenance and effects of dose reduction following prolonged treatment with baricitinib. <i>Rheumatology</i> , 2018, 57, . | 1.9 | 0 |
| 430 | 182â€¦Secukinumab provides sustained improvement in function, quality of life and fatigue over two years in patients who achieved disease activity index for psoriatic arthritis remission. <i>Rheumatology</i> , 2018, 57, . | 1.9 | 0 |
| 431 | 184â€¦Secukinumab provides sustained remission and low disease activity related to disease activity index for psoriatic arthritis: two year results from the FUTURE 2 study. <i>Rheumatology</i> , 2018, 57, . | 1.9 | 0 |
| 432 | Greetings from the editor. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 715-715. | 0.9 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 433 | THU0431â€¦FREQUENCY OF TENDON INVOLVEMENT AND ITS EFFECT ON HAND FUNCTION IN HAND OSTEOARTHRITIS. , 2019, , . | | 0 |
| 434 | AB1219â€¦EFFECTS OF A WORKPLACE-CENTERED COUNSELING OF INDIVIDUALS WITH MUSCULOSKELETAL COMPLAINTS: A PROSPECTIVE COHORT STUDY. , 2019, , . | | 0 |
| 435 | THU0101â€¦TORQUE TENO VIRAL LOAD FOR MONITORING OF BIOLOGICAL THERAPIES IN RHEUMATOID ARTHRITIS. , 2019, , . | | 0 |
| 436 | OPO229PHASEâ€¦II CLINICAL TRIALS SYSTEMATICALLY OVERESTIMATE TREATMENT EFFECTS OF SUBSEQUENT PHASE III TRIALS IN RHEUMATOID ARTHRITIS. , 2019, , . | | 0 |
| 437 | SAT0061â€¦IMPORTANT ROLE OF CD11C+ CELLSIN INFLAMMATORY ARTHRITIS. , 2019, , . | | 0 |
| 438 | SAT0162â€¦A POOLED ANALYSIS OF 1-YEAR CLINICAL OUTCOMES AMONG 6-MONTH RESPONDERS AND NON-RESPONDERS FROM THREE RANDOMISED CONTROLLED STUDIES OF TNF INHIBITOR BIOSIMILARS IN PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , . | | 0 |
| 439 | LB0005â€¦MULTICENTRE, RANDOMISED, OPEN-LABEL, ASSESSOR-BLINDED, PARALLEL-GROUP HEAD-TO-HEAD COMPARISON OF THE EFFICACY AND SAFETY OF IXEKIZUMAB VERSUS ADALIMUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS NAIVE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: 24-WEEK RESULTS. , 2019, , . | | 0 |
| 440 | THU0133â€¦TENDERNESS CAN BE REGARDED AS A SIGN OF INFLAMMATION IN RHEUMATOID ARTHRITIS. , 2019, , . | | 0 |
| 441 | P276â€¦Comparative effects of ixekizumab (IXE) vs adalimumab (ADA) across PsA patients defined by baseline characteristics: week 24 outcomes from SPIRIT-H2H. Rheumatology, 2020, 59, . | 1.9 | 0 |
| 442 | Response to: â€”Comment on â€”Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumabâ€”â™™ by Pethoe-Schramm<i>et al</i>. Annals of the Rheumatic Diseases, 2022, 81, e137-e137. | 0.9 | 0 |
| 443 | O4â€¦Baricitinib-induced changes in STAT-associated gene expression in systemic lupus erythematosus. , 2020, , . | | 0 |
| 444 | O8â€¦Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematosus in men, ethnicities, and early disease. , 2020, , . | | 0 |
| 445 | Risk of harm in synthetic and biological intervention trials in patients with inflammatory arthritis: protocol for a metaepidemiological study focusing on contextual factors. BMJ Open, 2021, 11, e049850. | 1.9 | 0 |
| 446 | Novel therapies in rheumatoid arthritis: small molecules. , 2015, , 251-266. | | 0 |
| 447 | O24â€¦Concomitant treatment with MTX does not increase the efficacy of ustekinumab or TFNi in PsA: results from the PsABio study. Rheumatology, 2020, 59, . | 1.9 | 0 |